The Australian Government is now in caretaker period. During this time, updates on this website will be published in accordance with the Guidance on Caretaker Conventions, until after the election.
2709 results found
In conjunction with the Australian Clinical Trials Alliance, we developed the clinical trials competencies to be used in the development of detailed curricula and training courses by universities, Colleges and other registered training organisations*.
Part 2 of the Freedom of Information Act 1982 establishes the Information Publication Scheme (IPS) for Australian Government agencies subject to the Act. The IPS requires agencies to publish a broad range of information on their websites and to list certain documents that are not available online with detail of how they can be accessed.
The NHMRC and ARC Statement on Open Researcher and Contributor ID explains NHMRC's position on the ORCID researcher identifier.
When working with research that involves human embryos created by assisted reproductive technology (ART), it can be difficult to determine if a licence is required for training and quality assurance activities. The attached documents provide information and helpful links to help identify legislative requirements.
Leukaemias are difficult-to-treat blood cancers, which are common among both young and older people. In Australia in 2023, around 20,000 people were diagnosed with a blood cancer and blood cancers accounted for an estimated 38% of all cancer cases among the 0–19 year-old age group. Over 5,000 Australians die each year from blood cancers.1 NHMRC-funded researchers at WEHI have made revolutionary breakthroughs in our understanding of leukaemia biology, leading to the development of a new type of anti-cancer drug, venetoclax, that has significantly improved treatment for leukaemia patients.
Australia’s capacity for health and medical research translation is receiving a $3.7 million funding boost to help improve public health policy and service delivery.